SOURCE: CZ BioMed Corp.

August 23, 2011 10:24 ET

CZ BioMed Corp. Names Internationally Renowned Dr. Ronald E. Wheeler, M.D. as Medical Director of Its Scientific and Medical Advisory Boards

CZ BioMed Corp. -- Research for Cancer Cure -- RVLYSIN®

TAMPA, FL--(Marketwire - Aug 23, 2011) - CZ BioMed Corp., a leading company in the field of oncolytic virotherapy, providing research, development, commercialization and treatments, pursuant to the eradication of various cancers, announced today the appointment of Dr. Ronald E. Wheeler, M.D. to lead its Medical Advisory Board, in charge of prostate cancer clinical trials studies worldwide.

CZ BioMed Corp. CEO, Calvin Cao, said, "We welcome Dr. Wheeler to our advisory boards with enthusiasm. He is a very distinguished and highly recognized international expert with years of cutting edge laboratory and clinical management experience in the fields of urology and prostate cancer. He will be pivotal in the development of both safety and administration protocols for our patent pending oncolytic virotherapy cancer treatments worldwide. His impeccable track record further adds credibility to our talented staff and supports our goal of eradicating cancers worldwide."

Dr. Wheeler said, "With its technologies, patent base, global affiliations, and many successful demonstrated results eradicating tumors in-vitro and in-vivo, CZ BioMed is well positioned to become the breakthrough leader in the fight against cancer. I am excited to be a part of such an innovative company with such excellent humanitarian motivations. I expect us to demonstrate tremendous advances in the treatment of many cancers in the very near future."

About Dr. Ronald Wheeler, M.D.: A practicing Urologist for more than 20 years, Dr. Wheeler has focused on male related health issues including impotency and Prostate Diseases associated with BPH, Prostatitis, and Prostate Cancer. He has been a member of the American Urologic Association since 1985 and is a member of the National Institute of Health (NIH) "Prostatitis Collaborative."

He is currently Medical Director of the Diagnostic Center for Disease located in Sarasota, FL and of the Prostate Cancer Prevention Foundation.

Other professional highlights include:

  • Owner of two patents on Prostatitis Detection and Resolution
  • Principal investigator in a "Neo-Adjuvant study for Organ Confined Prostate Cancer," by Schering Pharmaceuticals
  • A member of the esteemed Royal College of Alternative Medicine (RCAM)
  • Certified in High Intensity Focused Ultrasound (HIFU), a novel prostate cancer treatment currently involved in Phase 3 trials at the FDA. Currently treating patients in Canada, Dominican Republic, Mexico, and the Bahamas
  • Author of numerous prostate related articles
  • Member of Advisory boards for several health realated corporations and foundations including: Sanofi-Aventis Ocoology, Urology Times, PAACT, Prostate Awareness Foundation, Glaxo Smith Kline, Abbott, and Radiation Centers of America
  • Frequent Speaker on various radio stations and, meetings, and related symposiums

About CZ BioMed Corp.:

CZ BioMed Corp. is a privately held Biotechnology company based in Tampa, FL, focused on the discovery, development and commercialization of a new class of high-tech biological products for the treatment of a wide variety of human cancers. CZ BioMed products use novel oncolytic viruses that have been genetically engineered to selectively target tumor cells, but not normal healthy cells. The mission of CZ BioMed Corp. is rooted in the knowledge of our invention with the products we provide positively affecting the quality of patients lives. Since everything we do, no matter how small, impacts the end product and ultimately people's lives, we accept only the highest ethical and quality standards, both from ourselves and others.

For further information about CZ BioMed Corp. please visit: www.czbiomed.com.

Forward Looking Statements

This report includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and general economic risks and uncertainties.

Contact Information

  • FOR FURTHER INFORMATION
    CONTACT:
    CZ BioMed Corp.
    info@czbiomed.com
    Phone: 813-600-4088